Ownership and insider activity for Twist Bioscience Corporation (TWST): insider transactions, US Senate and House trading disclosures and shares outstanding. Track how corporate insiders and politicians are trading the stock.
Twist Bioscience Corporation operates as a leading synthetic biology firm, specializing in the production and sale of products developed from synthesized DNA. The company utilizes a unique DNA synthesis platform that facilitates the creation of artificial DNA by "writing" it directly onto silicon chips.
Price
| Price | $205.00 |
| Market Cap | $12.8B |
| Exchange | NASDAQ |
| Country | US |
Recent Insider Transactions
| Date | Insider | Type | Shares | Value |
|---|---|---|---|---|
| 2026-10-02 | Laponis Adam | S-Sale | 8,057 | $1.5M |
| 2026-10-02 | Green Paula | S-Sale | 10,088 | $1.9M |
| 2026-10-02 | Finn Patrick John | S-Sale | 25,714 | $4.9M |
| 2026-10-01 | Leproust Emily M. | S-Sale | 655 | $131K |
| 2026-10-02 | Leproust Emily M. | S-Sale | 45,736 | $8.6M |
| 2026-10-02 | Cho Dennis | S-Sale | 9,514 | $1.8M |
| 2026-10-02 | WERNER ROBERT F. | S-Sale | 1,482 | $280K |
| 2026-09-24 | Leproust Emily M. | S-Sale | 2,485 | $435K |
| 2026-09-24 | Leproust Emily M. | S-Sale | 945 | $167K |
| 2026-09-24 | Leproust Emily M. | S-Sale | 164 | $29K |
Balance Sheet (10y)
| Year | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $28.6M | $31.2M | $80.8M | $46.7M | $93.7M | $465.8M | $378.7M | $286.5M | $226.3M | $183.0M |
| Short-term Investments | $27.3M | $31.0M | 0 | $91.4M | $196.3M | $12.0M | $126.3M | $49.9M | $50.1M | $49.4M |
| Receivables | $723,000 | $2.3M | $5.4M | $12.1M | $25.4M | $28.5M | $40.3M | $44.1M | $34.9M | $57.3M |
| Inventory | $1.2M | $1.8M | $6.0M | $7.3M | $12.3M | $31.8M | $39.3M | $32.1M | $24.1M | $28.3M |
| Total Current Assets | $59.0M | $67.9M | $95.7M | $160.1M | $334.9M | $546.5M | $596.5M | $424.3M | $346.8M | $333.0M |
| Property, Plant & Equipment | $14.6M | $14.8M | $12.3M | $20.8M | $59.2M | $105.7M | $214.4M | $203.4M | $161.3M | $151.7M |
| Goodwill | $1.1M | $1.1M | $1.1M | $1.1M | $1.1M | $22.4M | $85.8M | $85.8M | $85.8M | $82.2M |
| Intangible Assets | $1.1M | $920,000 | $712,000 | $508,000 | $307,000 | $18.3M | $59.7M | $54.5M | $14.5M | $13.4M |
| Total Assets | $76.5M | $85.7M | $115.8M | $187.0M | $398.9M | $702.1M | $961.4M | $776.4M | $614.3M | $641.9M |
| Accounts Payable | $2.3M | $2.8M | $7.5M | $9.8M | $4.8M | $14.9M | $20.1M | $14.1M | $1.6M | $11.1M |
| Short-term Debt | $1.4M | 0 | $2.5M | $3.3M | $3.3M | $1.6M | 0 | 0 | 0 | $13.8M |
| Total Current Liabilities | $8.7M | $9.5M | $18.5M | $30.4M | $36.0M | $63.1M | $90.7M | $73.3M | $71.0M | $91.4M |
| Long-term Debt | $9.8M | $9.2M | $7.2M | $4.4M | $1.4M | 0 | 0 | 0 | 0 | $61.8M |
| Total Liabilities | $153.1M | $219.0M | $317.2M | $34.9M | $62.6M | $121.3M | $172.0M | $153.0M | $141.6M | $168.9M |
| Retained Earnings | -$80.3M | -$139.6M | -$210.9M | -$318.5M | -$458.5M | -$610.6M | -$828.4M | -$1.03B | -$1.24B | -$1.32B |
| Total Equity | -$76.6M | -$133.4M | -$201.4M | $152.1M | $336.3M | $580.8M | $789.4M | $623.4M | $472.7M | $473.0M |
| Total Debt | $11.2M | $9.2M | $9.7M | $7.7M | $36.0M | $62.9M | $94.9M | $94.1M | $85.0M | $137.3M |
| Net Debt | -$44.7M | -$53.0M | -$71.0M | -$130.4M | -$254.0M | -$414.9M | -$410.1M | -$242.3M | -$191.4M | -$95.1M |
| Working Capital | $50.4M | $58.4M | $77.1M | $129.8M | $298.8M | $483.4M | $505.8M | $350.9M | $275.8M | $241.6M |
Financial Health
| Debt / Equity | 0.21 |
| Current Ratio | 2.67 |
| Piotroski F-Score | 4 |
| Altman Z-Score | 3.44 |
Profitability
| Return on Equity | -29.89% |
| Return on Invested Capital | -24.57% |
| Return on Assets | -20.33% |
| Gross Margin | 51.97% |
| Operating Margin | -31.91% |
| Net Margin | -31.66% |
Related companies: BGM · CLOV · EWTX · GPCR · GRDN · MESO · PRCT
Explore sector: Healthcare · Biotechnology
More sections of TWST: Overview · Financials · Valuation · Statistics · Estimates · Technical · News · Events
Discover more: Weekly Radar: the S&P 500 through the Buffett and Lynch methods · Investment Academy — learn to analyze stocks